Shaun Roe
Family Medicine · Belmont, OHNPI 1750558797
Payments from drug & device makers
Across 364 payments — averaging $13.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$823
- AbbVie$801
- Merck$546
- AstraZeneca$488
- Lilly USA, LLC$459
- Boehringer Ingelheim$402
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,95399%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 77 | $823 |
| AbbVie(2 entities) | 59 | $801 |
| Merck | 38 | $546 |
| AstraZeneca | 27 | $488 |
| Lilly USA, LLC | 36 | $459 |
| Boehringer Ingelheim | 30 | $402 |
| Amgen | 20 | $305 |
| Johnson & Johnson | 12 | $171 |
| Amarin Pharma, Inc. | 10 | $157 |
| Teva Pharmaceuticals USA, Inc. | 9 | $132 |
| Pfizer | 7 | $113 |
| GSK | 5 | $85 |
| E.r. Squibb & Sons, L.L.C. | 5 | $76 |
| Upsher-smith Laboratories LLC | 3 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Abbott | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Novartis | 2 | $29 |
| Shire North American Group Inc | 2 | $28 |
| Organon | 3 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$5,007 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $168,575 |
| MounjaroTirzepatide | 85 | $117,033 |
| EliquisApixaban | 108 | $94,397 |
| JardianceEmpagliflozin | 71 | $87,400 |
| FarxigaDapagliflozin Propanediol | 84 | $78,778 |
| Humira(Cf) PenAdalimumab | 11 | $69,782 |
| TrulicityDulaglutide | 54 | $63,158 |
| FanaptIloperidone | 13 | $20,853 |
| XareltoRivaroxaban | 17 | $17,529 |
| LamictalLamotrigine | 12 | $17,364 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $17,340 |
| LinzessLinaclotide | 30 | $16,614 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,431 |
| JanuviaSitagliptin Phosphate | 22 | $15,202 |
| VascepaIcosapent Ethyl | 30 | $12,812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $459 | $180,191139 claims |
| Novo NordiskOzempic | $823 | $168,575136 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Tradjenta | $402 | $113,161113 claims |
| PfizerEliquis | $113 | $94,397108 claims |
| AstraZenecaFarxiga | $488 | $78,77884 claims |
| GSKLamictal, Trelegy Ellipta, Shingrix, Arexvy | $85 | $48,364104 claims |
| Johnson & JohnsonXarelto | $171 | $17,52917 claims |
| AbbVieLinzess | $801 | $16,61430 claims |
| MerckJanuvia | $546 | $15,20222 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $12 | $2,33513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Belmont
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.